Chronic obstructive pulmonary disease treated with inhaled medium- or high-dose corticosteroids: a prospective and randomized study focusing on clinical efficacy and the risk of pneumonia

被引:17
作者
Cheng, Shih-Lung [1 ,2 ]
Su, Kang-Cheng [3 ]
Wang, Hao-Chien [4 ]
Perng, Diahn-Warng [3 ]
Yang, Pan-Chyr [4 ]
机构
[1] Far Eastern Mem Hosp, Dept Internal Med, New Taipei City, Taiwan
[2] Yuan Ze Univ, Dept Chem Engn & Mat Sci, Zhongli City, Taoyuan County, Taiwan
[3] Taipei Vet Gen Hosp, Dept Chest Med, Taipei, Taiwan
[4] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan
关键词
chronic obstructive pulmonary disease; pneumonia; inhaled corticosteroids; FLUTICASONE PROPIONATE/SALMETEROL 250/50; COMMUNITY-ACQUIRED PNEUMONIA; COPD EXACERBATIONS; DIABETES-MELLITUS; UNITED-STATES; SALMETEROL; METAANALYSIS; MORTALITY; IMPACT; TRIAL;
D O I
10.2147/DDDT.S63100
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Purpose: Complications of pneumonia development in patients with chronic obstructive pulmonary disease (COPD) receiving inhaled corticosteroid (ICS) therapy have been documented. The aim of this study was to focus on clinical efficacy and the incidence of pneumonia between COPD patients receiving medium and high doses of ICS. Patients and methods: This prospective, randomized study included COPD patients identified from three tertiary medical centers from 2010 to 2012. The patients were randomized into two groups: high dose (HD; fluticasone 1,000 mu g + salmeterol 100 mu g/day) and medium dose (MD; fluticasone 500 mu g + salmeterol 100 mu g/day). Lung function with forced expiratory volume in 1 second (FEV1), forced vital capacity, and COPD-assessment test (CAT) were checked every 2 months. The frequency of acute exacerbations and number of pneumonia events were measured. The duration of the study period was 1 year. Results: In total, 237 COPD patients were randomized into the two treatment arms (115 in the HD group, 122 in the MD group). The FEV1 level was significantly improved in the patients in the HD group compared with those in the MD group (HD 103.9 +/- 26.6 mL versus MD 51.4 +/- 19.7 mL, P<0.01) at the end of the study. CAT scores were markedly improved in patients using an HD compared to those using an MD (HD 13 +/- 5 versus MD 16 +/- 7, P=0.05). There was a significant difference in the percentage of annual rates in acute exacerbations (HD 0.16 versus MD 0.34, P<0.01) between the two groups. The incidence of pneumonia was similar in the two groups (HD 0.08 versus MD 0.10, P=0.38). Conclusion: COPD patients treated with high doses of ICS had more treatment benefits and no significant increases in the incidence in pneumonia. Higher-dose ICS treatment may be suitable for COPD therapy.
引用
收藏
页码:601 / 607
页数:7
相关论文
共 45 条
[31]   Incidence and Cost of Pneumonia in Older Adults with COPD in the United States [J].
Ryan, Marian ;
Suaya, Jose A. ;
Chapman, John D. ;
Stason, William B. ;
Shepard, Donald S. ;
Thomas, Cindy Parks .
PLOS ONE, 2013, 8 (10)
[32]   Chronic obstructive pulmonary disease and inhaled steroids alter surfactant protein D (SP-D) levels: a cross-sectional study [J].
Sims, Michael W. ;
Tal-Singer, Ruth M. ;
Kierstein, Sonja ;
Musani, Ali I. ;
Beers, Michael F. ;
Panettieri, Reynold A. ;
Haczku, Angela .
RESPIRATORY RESEARCH, 2008, 9 (1)
[33]   Budesonide and the risk of pneumonia: a meta-analysis of individual patient data [J].
Sin, Don D. ;
Tashkin, Donald ;
Zhang, Xuekui ;
Radner, Finn ;
Sjobring, Ulf ;
Thoren, Anders ;
Calverley, Peter M. A. ;
Rennard, Stephen I. .
LANCET, 2009, 374 (9691) :712-719
[34]   Impact of inhaled corticosteroid use on outcome in COPD patients admitted with pneumonia [J].
Singanayagam, A. ;
Chalmers, J. D. ;
Akram, A. R. ;
Hill, A. T. .
EUROPEAN RESPIRATORY JOURNAL, 2011, 38 (01) :36-41
[35]   Long-term Use of Inhaled Corticosteroids and the Risk of Pneumonia in Chronic Obstructive Pulmonary Disease A Meta-analysis [J].
Singh, Sonal ;
Amin, Aman V. ;
Loke, Yoon K. .
ARCHIVES OF INTERNAL MEDICINE, 2009, 169 (03) :219-229
[36]   Inhaled corticosteroids and the risk of pneumonia in Medicare patients with COPD [J].
Snider, Julia Thornton ;
Luna, Yesenia ;
Wong, Ken S. ;
Zhang, Jie ;
Chen, Susan S. ;
Gless, Patrick J. ;
Goldman, Dana P. .
CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (12) :1959-1967
[37]   Impact of preventing exacerbations on deterioration of health status in COPD [J].
Spencer, S ;
Calverley, PMA ;
Burge, PS ;
Jones, PW .
EUROPEAN RESPIRATORY JOURNAL, 2004, 23 (05) :698-702
[38]   Inhaled corticosteroids in COPD and the risk of serious pneumonia [J].
Suissa, Samy ;
Patenaude, Valerie ;
Lapi, Francesco ;
Ernst, Pierre .
THORAX, 2013, 68 (11) :1029-1036
[39]   Inhaled Corticosteroids and the Risks of Diabetes Onset and Progression [J].
Suissa, Samy ;
Kezouh, Abbas ;
Ernst, Pierre .
AMERICAN JOURNAL OF MEDICINE, 2010, 123 (11) :1001-1006
[40]   Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease [J].
Szafranski, W ;
Cukier, A ;
Ramirez, A ;
Menga, G ;
Sansores, R ;
Nahabedian, S ;
Peterson, S ;
Olsson, H .
EUROPEAN RESPIRATORY JOURNAL, 2003, 21 (01) :74-81